October 16, 2017
Please join AVAC and partners for two upcoming webinars, 10am ET on Thursday, October 26 and 9am ET on Friday, October 27. Thursday’s webinar is in partnership with the Treatment Action Group (TAG) and offers a chance to discuss the role of PrEP in HIV prevention trials. Friday’s webinar is with the head of the US NIH Division of AIDS, Dr. Carl Dieffenbach, and provides an additional opportunity to talk about the focus and priorities for the NIH-funded HIV clinical trial networks. Both are juicy topics so please do join for what should be great conversations!
- (10/26) HIV Research in the Era of PrEP: The implications of TDF/FTC for biomedical prevention trials
- (10/27) Informing the Research Enterprise: Webinar with Carl Dieffenbach on future priorities for HIV research networks
On Thursday, October 26, at 10am ET join colleagues from the Treatment Action Group (TAG), along with advocates, researchers and GPP practitioners, to discuss the recommendations from TAG’s recently released white paper, HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials. The effectiveness and increasing availability of oral PrEP raises questions about how it should be incorporated into clinical trial designs for next-generation HIV prevention options. This paper explores ethics, the scientific literature to date, and advocates’ views on the issue.
Friday, October 27 at 9am ET is the second webinar in a series with Dr. Carl Dieffenbach, Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy and Infectious Diseases. A recording of the first webinar is available here. Given the great interest in the topic we are offering another occasion to talk with Dr. Dieffenbach, and at an earlier time to accommodate additional time zones.
As background, every seven years, the NIH reviews the structure and funding of its HIV clinical research networks. This “network recompetition” process involves decisions that will help determine the focus and priorities of its HIV clinical trial networks through 2027, as well as the number and structures of the various networks that undertake this research. These are critical questions for advocates to weigh in on—whether you are in the US or not.